PLGA 50:50 nanoparticles of paclitaxel: Development, in vitro anti-tumor activity in BT-549 cells and in vivo evaluation

Ranjith K. Averineni, Gopal V. Shavi, Aravind K. Gurram, Praful B. Deshpande, Karthik Arumugam, Naseer Maliyakkal, Sreenivasa R. Meka, Udupa Nayanabhirama

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Clinical administration of paclitaxel is hindered due to its poor solubility, which necessitates the formulation of novel drug delivery systems to deliver such extreme hydrophobic drug. To formulate nanoparticles which makes suitable to deliver hydrophobic drugs effectively (intravenous) with desired pharmacokinetic profile for breast cancer treatment; in this context in vitro cytotoxic activity was evaluated using BT-549 cell line. PLGA nanoparticles were prepared by emulsion solvent evaporation technique and evaluated for physicochemical parameters, in vitro anti-tumor activity and in vivo pharmacokinetic studies in rats. Particle size obtained in optimized formulation was <200 nm. Encapsulation efficiency was higher at polymer-to-drug ratio of 20:1. In vitro drug release exhibited biphasic pattern with initial burst release followed by slow and continuous release (15 days). In vitro anti-tumor activity of optimized formulation inhibited cell growth for a period of 168 h against BT-549 cells. AUC (0-∞) and t 1/2 were found to be higher for nanoparticles with low clearance rate.

Original languageEnglish
Pages (from-to)319-326
Number of pages8
JournalBulletin of Materials Science
Volume35
Issue number3
DOIs
Publication statusPublished - 01-06-2012

Fingerprint

Paclitaxel
Tumors
Pharmacokinetics
Nanoparticles
Pharmaceutical Preparations
Oncology
Cell growth
Encapsulation
Emulsions
Rats
Evaporation
Solubility
Particle size
Cells
Polymers
polylactic acid-polyglycolic acid copolymer

All Science Journal Classification (ASJC) codes

  • Materials Science(all)
  • Mechanics of Materials

Cite this

Averineni, Ranjith K. ; Shavi, Gopal V. ; Gurram, Aravind K. ; Deshpande, Praful B. ; Arumugam, Karthik ; Maliyakkal, Naseer ; Meka, Sreenivasa R. ; Nayanabhirama, Udupa. / PLGA 50:50 nanoparticles of paclitaxel : Development, in vitro anti-tumor activity in BT-549 cells and in vivo evaluation. In: Bulletin of Materials Science. 2012 ; Vol. 35, No. 3. pp. 319-326.
@article{c0a710e743e54cb8a74bab3eaaa6c5b4,
title = "PLGA 50:50 nanoparticles of paclitaxel: Development, in vitro anti-tumor activity in BT-549 cells and in vivo evaluation",
abstract = "Clinical administration of paclitaxel is hindered due to its poor solubility, which necessitates the formulation of novel drug delivery systems to deliver such extreme hydrophobic drug. To formulate nanoparticles which makes suitable to deliver hydrophobic drugs effectively (intravenous) with desired pharmacokinetic profile for breast cancer treatment; in this context in vitro cytotoxic activity was evaluated using BT-549 cell line. PLGA nanoparticles were prepared by emulsion solvent evaporation technique and evaluated for physicochemical parameters, in vitro anti-tumor activity and in vivo pharmacokinetic studies in rats. Particle size obtained in optimized formulation was <200 nm. Encapsulation efficiency was higher at polymer-to-drug ratio of 20:1. In vitro drug release exhibited biphasic pattern with initial burst release followed by slow and continuous release (15 days). In vitro anti-tumor activity of optimized formulation inhibited cell growth for a period of 168 h against BT-549 cells. AUC (0-∞) and t 1/2 were found to be higher for nanoparticles with low clearance rate.",
author = "Averineni, {Ranjith K.} and Shavi, {Gopal V.} and Gurram, {Aravind K.} and Deshpande, {Praful B.} and Karthik Arumugam and Naseer Maliyakkal and Meka, {Sreenivasa R.} and Udupa Nayanabhirama",
year = "2012",
month = "6",
day = "1",
doi = "10.1007/s12034-012-0313-7",
language = "English",
volume = "35",
pages = "319--326",
journal = "Bulletin of Materials Science",
issn = "0250-4707",
publisher = "Indian Academy of Sciences",
number = "3",

}

PLGA 50:50 nanoparticles of paclitaxel : Development, in vitro anti-tumor activity in BT-549 cells and in vivo evaluation. / Averineni, Ranjith K.; Shavi, Gopal V.; Gurram, Aravind K.; Deshpande, Praful B.; Arumugam, Karthik; Maliyakkal, Naseer; Meka, Sreenivasa R.; Nayanabhirama, Udupa.

In: Bulletin of Materials Science, Vol. 35, No. 3, 01.06.2012, p. 319-326.

Research output: Contribution to journalArticle

TY - JOUR

T1 - PLGA 50:50 nanoparticles of paclitaxel

T2 - Development, in vitro anti-tumor activity in BT-549 cells and in vivo evaluation

AU - Averineni, Ranjith K.

AU - Shavi, Gopal V.

AU - Gurram, Aravind K.

AU - Deshpande, Praful B.

AU - Arumugam, Karthik

AU - Maliyakkal, Naseer

AU - Meka, Sreenivasa R.

AU - Nayanabhirama, Udupa

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Clinical administration of paclitaxel is hindered due to its poor solubility, which necessitates the formulation of novel drug delivery systems to deliver such extreme hydrophobic drug. To formulate nanoparticles which makes suitable to deliver hydrophobic drugs effectively (intravenous) with desired pharmacokinetic profile for breast cancer treatment; in this context in vitro cytotoxic activity was evaluated using BT-549 cell line. PLGA nanoparticles were prepared by emulsion solvent evaporation technique and evaluated for physicochemical parameters, in vitro anti-tumor activity and in vivo pharmacokinetic studies in rats. Particle size obtained in optimized formulation was <200 nm. Encapsulation efficiency was higher at polymer-to-drug ratio of 20:1. In vitro drug release exhibited biphasic pattern with initial burst release followed by slow and continuous release (15 days). In vitro anti-tumor activity of optimized formulation inhibited cell growth for a period of 168 h against BT-549 cells. AUC (0-∞) and t 1/2 were found to be higher for nanoparticles with low clearance rate.

AB - Clinical administration of paclitaxel is hindered due to its poor solubility, which necessitates the formulation of novel drug delivery systems to deliver such extreme hydrophobic drug. To formulate nanoparticles which makes suitable to deliver hydrophobic drugs effectively (intravenous) with desired pharmacokinetic profile for breast cancer treatment; in this context in vitro cytotoxic activity was evaluated using BT-549 cell line. PLGA nanoparticles were prepared by emulsion solvent evaporation technique and evaluated for physicochemical parameters, in vitro anti-tumor activity and in vivo pharmacokinetic studies in rats. Particle size obtained in optimized formulation was <200 nm. Encapsulation efficiency was higher at polymer-to-drug ratio of 20:1. In vitro drug release exhibited biphasic pattern with initial burst release followed by slow and continuous release (15 days). In vitro anti-tumor activity of optimized formulation inhibited cell growth for a period of 168 h against BT-549 cells. AUC (0-∞) and t 1/2 were found to be higher for nanoparticles with low clearance rate.

UR - http://www.scopus.com/inward/record.url?scp=84863495964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863495964&partnerID=8YFLogxK

U2 - 10.1007/s12034-012-0313-7

DO - 10.1007/s12034-012-0313-7

M3 - Article

AN - SCOPUS:84863495964

VL - 35

SP - 319

EP - 326

JO - Bulletin of Materials Science

JF - Bulletin of Materials Science

SN - 0250-4707

IS - 3

ER -